Current Diabetes Reports

, Volume 3, Issue 1, pp 65–72 | Cite as

Lipid abnormalities in the metabolic syndrome

  • Eliot A. Brinton
Article

Abstract

The metabolic syndrome is the constellation of adverse metabolic and clinical effects of insulin resistance. Its high and increasing prevalence and its profound impact on the major diseases of the western world require that clinicians consider its diagnosis and management on a routine basis. Recently published guidelines on its definition now make convenient and reliable diagnosis possible. Also, there is new and better understanding of the complex dyslipidemias and other risk factors strongly associated with the metabolic syndrome, which greatly increase the risk of clinical atherosclerotic events. Comprehensive clinical evaluation of these dyslipidemias and associated atherosclerosis risk factors can lead to their aggressive treatment, customized according to the circumstances of each patient. These steps are now more feasible and more clearly desirable than ever before. Statins alone greatly reduce atherosclerosis risk, but combination lipid therapy is often required for optimal dyslipidemia management and atheroprevention.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group [no authors listed]. N Engl J Med 2002, 346:393–403. Dramatic reduction of diabetes incidence in impaired glucose tolerance with metformin, whereas diet and exercise were even more effective.CrossRefGoogle Scholar
  2. 2.
    Ford E, Giles W, Dietz WH, et al.: Prevalence of the metabolic syndrome among US adults. JAMA 2002, 287:356–359. First study to apply the NCEP ATP III guidelines for the metabolic syndrome (insulin resistance) in a large population, showing very high prevalence of nearly one-quarter among US adults.PubMedCrossRefGoogle Scholar
  3. 3.
    Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979, 241:2035–2038.PubMedCrossRefGoogle Scholar
  4. 4.
    Keen H, Rose G, Pyke DA, et al.: Blood-sugar and arterial disease. Lancet 1965, 2:505–508.PubMedCrossRefGoogle Scholar
  5. 5.
    Isomaa B, Almgren P: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689.PubMedCrossRefGoogle Scholar
  6. 6.
    Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998, 15:539–553.PubMedCrossRefGoogle Scholar
  7. 7.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) [no authors listed]. JAMA 2001, 285:2486–2497. Current guidelines for lipid management in atheroprevention; new emphasis on diabetes mellitus, insulin resistance, and global risk.CrossRefGoogle Scholar
  8. 8.
    National Diabetes Data Group: Diabetes in America, edn. 2. Bethesda, MD: Nations Institutes of Health; 1995.Google Scholar
  9. 9.
    Fontbonne AM, Eschwege EM: Insulin and cardiovascular disease. Diabetes Care 1991, 14:461–469.PubMedCrossRefGoogle Scholar
  10. 10.
    Kanaya A, Grady D, Barrett-Conner E: Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus. Arch Intern Med 2002, 162:1737–1745.PubMedCrossRefGoogle Scholar
  11. 11.
    Gu K, Cowie C, Harris M: Diabetes and decline in heart disease mortality in US adults. JAMA 1999, 281:1291–1297.PubMedCrossRefGoogle Scholar
  12. 12.
    Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.PubMedCrossRefGoogle Scholar
  13. 13.
    Lotufo P, Gaziano M, Chae CU, et al.: Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med 2001, 161:242–247.PubMedCrossRefGoogle Scholar
  14. 14.
    Caballero AE, Arora S, Saouaf R, et al.: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999, 48:1856–1862.PubMedCrossRefGoogle Scholar
  15. 15.
    Feener EP, King GL: Vascular dysfunction in diabetes mellitus. Lancet 1997, 350(suppl 1):S19-S13.Google Scholar
  16. 16.
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators [no authors listed]. The Lancet 2000, 355:253–259.Google Scholar
  17. 17.
    Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. N Engl J Med 2000, 342:145–153.Google Scholar
  18. 18.
    Rexrode KM, Carey VJ, Hennekens CH, et al.: Abdominal adiposity and coronary heart disease in women. JAMA 1998, 280:1843–1848.PubMedCrossRefGoogle Scholar
  19. 19.
    Festa A, D’Agostino RD Jr, Mykkanen L, et al.: Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. Arterioscler Thromb Vasc Biol 1999, 19:562–568.PubMedGoogle Scholar
  20. 20.
    Meigs J, Mittleman M, Nathan DM, et al.: Hyperinsulinemia, hyperglycemia, and impaired hemostasis. JAMA 2000, 283:221–228.PubMedCrossRefGoogle Scholar
  21. 21.
    Hofmann C, Lorenz K, Braithwaite SS, et al.: Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994, 134:264–270.PubMedCrossRefGoogle Scholar
  22. 22.
    Rossi E, Biasucci L, Citterio F, et al.: Risk of myocardial infarction and angina in patients with severe peripheral vascular disease. Circulation 2002, 105:800–803.PubMedCrossRefGoogle Scholar
  23. 23.
    Tan K, Chow W, Tam SC. et al.: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002, 87:563–568.PubMedCrossRefGoogle Scholar
  24. 24.
    Festa A, D’Agostinr RJr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study. Circulation 2000, 102:42–47.PubMedGoogle Scholar
  25. 25.
    Jialal I, Stein D, Balis D, et al.: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001, 103:1933–1935.PubMedGoogle Scholar
  26. 26.
    Verma S, Wang C, Li SH, et al.: A self-fulfilling prophecy C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913–919.PubMedCrossRefGoogle Scholar
  27. 27.
    Garg A, Grundy SM: Management of dyslipidemia in NIDDM. Diabetes Care 1990, 13:153–169.PubMedCrossRefGoogle Scholar
  28. 28.
    Haffner S, D’Agostino R, Mykkanen L, et al.: Insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 1999, 22:562–568.PubMedCrossRefGoogle Scholar
  29. 29.
    Tenkanen L, Pietila Manninen V, Manttari M: The triglyceride issue revisited. Arch Intern Med 1994, 154:2714–2720.PubMedGoogle Scholar
  30. 30.
    Stampfer M, Sacks F, Salvini S, et al.: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991, 325:373–381.PubMedCrossRefGoogle Scholar
  31. 31.
    Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993, 16:434–444.PubMedCrossRefGoogle Scholar
  32. 32.
    Gray RS, Robbins D, Wang W, et al.: Relation of LDL size to insulin resistance syndrome and coronary heart disease in american indians: the Strong Heart Study. Arterioscler Thromb Vasc Biol 1997, 17:2713–2720.PubMedGoogle Scholar
  33. 33.
    Howard BV, Cowan LD, Go O, et al.: Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study. Diabetes Care 1998, 21:1258–1265.PubMedCrossRefGoogle Scholar
  34. 34.
    Lamarche B, Tchernof A, Moorjani S: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:60–75.Google Scholar
  35. 35.
    Austin M, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495–506.PubMedGoogle Scholar
  36. 36.
    Management of Dyslipidemia in Adults With Diabetes. American Diabetes Association [no authors listed]. Diabetes Care 1999, 22:S56–S59.Google Scholar
  37. 37.
    MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Heart Protection Study Collaborative Group [no authors listed]. Lancet 2002, 360:7–22. Largest and most provocative event-based statin trial. Benefit seen in all subjects regardless of baseline LDL-C, but events were still proportional to on-treatment LDL-C.CrossRefGoogle Scholar
  38. 38.
    Downs J, Clearfield D, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998, 279:1615–1622.PubMedCrossRefGoogle Scholar
  39. 39.
    Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998, 98:2513–2519.PubMedGoogle Scholar
  40. 40.
    Randomised trial of cholesterol lowering 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [no authors listed]. Lancet 1994, 344:1383–1389.Google Scholar
  41. 41.
    Prevention of cardiovascular events and death with pravastatin in patients with coronary artery disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group [no authors listed]. N Engl J Med 1998, 339:1349–1357.Google Scholar
  42. 42.
    Pyorala K, Pedersen T, Kjekshus J, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997, 20:614–620.PubMedCrossRefGoogle Scholar
  43. 43.
    Haffner SM, Alexander CM, Cook TJ, et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999, 159:2627–2628.CrossRefGoogle Scholar
  44. 44.
    Athyros V, Papageorgiou A, et al.: Treatment with atorvastatin to the national cholesterol educational program goal versus "usual" care in secondary coronary heart disease prevention. Curr Med Res Opin 2002, 18:220–228. First event-based trial to test the effects of treating to the NCEP ATP III LDL-C goal.PubMedCrossRefGoogle Scholar
  45. 45.
    Sacks F: The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002, 90:139–143. First "consensus" guidelines to recommend a treatment goal for HDL-C.PubMedCrossRefGoogle Scholar
  46. 46.
    Elam MB, Hunninghake DB, Davis KB, et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA 2000, 284:1263–1270. Good evidence that glucose increases with regular niacin therapy in type 2 diabetes are only mild and temporary.PubMedCrossRefGoogle Scholar
  47. 47.
    Grundy S, Vega G, McGovern ME, et al.: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002, 162:1568–1576. Good evidence that glucose increases with extended-release niacin therapy in type 2 diabetes are only mild and temporary.PubMedCrossRefGoogle Scholar
  48. 48.
    Koskinen P, Manttari M, Manninen V, et al.: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820–825.PubMedCrossRefGoogle Scholar
  49. 49.
    Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410–418.PubMedCrossRefGoogle Scholar
  50. 50.
    Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Diabetes Atherosclerosis Study Investigators [no authors listed ]. Lancet 2001, 357:905–910.Google Scholar
  51. 51.
    Ballantyne CM, Olsson AG, Cook TJ, et al.: Influence of low HDL-C and elevated triglyceride on CHD events and response to simvastatin in 4S. Circulation 2001, 104:3046–3051.PubMedGoogle Scholar
  52. 52.
    Frick M, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987, 317:1237–1245.PubMedCrossRefGoogle Scholar
  53. 53.
    Koskinen P, Mantarri M, Manin V, et al.: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820–825.PubMedCrossRefGoogle Scholar
  54. 54.
    Brown BG, Zhao X-Q, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592. Simvastatin and niacin greatly reduce coronary angiographic progression and CHD events; addition of antioxidants antagonizes benefits.PubMedCrossRefGoogle Scholar
  55. 55.
    American Diabetes Association. Aspirin therapy in diabetes [no authors listed]. Diabetes Care 2002, 25:S78–S79.Google Scholar
  56. 56.
    American Diabetes Association. Treatment of hypertension in adults with diabetes [no authors listed]. Diabetes Care 2002, 25:S71–S73.Google Scholar

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • Eliot A. Brinton
    • 1
  1. 1.Department of Internal MedicineCarl T. Hayden VA Medical Center, Section of Metabolism,Endocrinology, & NutritionPhoenixUSA

Personalised recommendations